LS Investment Advisors LLC trimmed its position in Core Laboratories (NYSE:CLB) by 36.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,721 shares of the oil and gas company’s stock after selling 1,532 shares during the quarter. LS Investment Advisors LLC’s holdings in Core Laboratories were worth $298,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. The Manufacturers Life Insurance Company grew its stake in Core Laboratories by 63.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,128 shares of the oil and gas company’s stock worth $114,000 after buying an additional 439 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its stake in Core Laboratories by 60.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 1,096 shares of the oil and gas company’s stock worth $120,000 after buying an additional 414 shares during the last quarter. Advisory Services Network LLC grew its stake in Core Laboratories by 33.3% during the 2nd quarter. Advisory Services Network LLC now owns 1,365 shares of the oil and gas company’s stock worth $138,000 after buying an additional 341 shares during the last quarter. Toronto Dominion Bank grew its stake in Core Laboratories by 243.6% during the 3rd quarter. Toronto Dominion Bank now owns 1,866 shares of the oil and gas company’s stock worth $184,000 after buying an additional 1,323 shares during the last quarter. Finally, Callahan Advisors LLC bought a new position in Core Laboratories during the 4th quarter worth $201,000.
CLB has been the subject of a number of analyst reports. TheStreet upgraded Core Laboratories from a “c” rating to a “b-” rating in a research report on Thursday, February 1st. Royal Bank of Canada set a $110.00 price target on Core Laboratories and gave the stock a “buy” rating in a research report on Thursday, December 21st. Loop Capital set a $115.00 price target on Core Laboratories and gave the stock a “buy” rating in a research report on Thursday, December 7th. Deutsche Bank lowered Core Laboratories from a “buy” rating to a “hold” rating and reduced their price target for the stock from $116.30 to $109.00 in a research report on Thursday, January 11th. Finally, ABN Amro lowered Core Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. Core Laboratories has a consensus rating of “Hold” and an average target price of $111.60.
Shares of Core Laboratories (NYSE CLB) traded up $1.25 during trading on Wednesday, hitting $107.94. The stock had a trading volume of 333,090 shares, compared to its average volume of 531,861. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.66 and a current ratio of 1.98. The firm has a market capitalization of $4,770.00, a price-to-earnings ratio of 56.51 and a beta of 1.47. Core Laboratories has a twelve month low of $86.55 and a twelve month high of $121.39.
Core Laboratories (NYSE:CLB) last announced its quarterly earnings data on Wednesday, January 31st. The oil and gas company reported $0.58 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.58. Core Laboratories had a return on equity of 58.25% and a net margin of 12.60%. The business had revenue of $172.00 million during the quarter, compared to analyst estimates of $171.92 million. During the same quarter in the prior year, the firm posted $0.41 earnings per share. The company’s revenue was up 15.1% on a year-over-year basis. equities research analysts expect that Core Laboratories will post 2.66 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, February 16th. Stockholders of record on Friday, January 26th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.04%. The ex-dividend date was Thursday, January 25th. Core Laboratories’s dividend payout ratio is 115.18%.
COPYRIGHT VIOLATION WARNING: “Core Laboratories (CLB) Position Trimmed by LS Investment Advisors LLC” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://ledgergazette.com/2018/03/14/core-laboratories-clb-shares-sold-by-ls-investment-advisors-llc.html.
Core Laboratories Company Profile
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.